請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55054
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林文澧(Wen-Li, Lin) | |
dc.contributor.author | Bing-Yu Yao | en |
dc.contributor.author | 姚秉瑜 | zh_TW |
dc.date.accessioned | 2021-06-16T03:45:38Z | - |
dc.date.available | 2017-03-13 | |
dc.date.copyright | 2015-03-13 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2015-02-04 | |
dc.identifier.citation | [1] Bae, Y. H. and K. Park., 'Targeted drug delivery to tumors: myths, reality and possibility.' J Control Release. 2011; 153(3): 198-205.
[2] Binion, D. G., et al., 'Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition.' Gut 2008; 57(11): 1509-1517. [3] Fukuda, T., et al. 'Pegylated liposomal doxorubicin for platinum-resistant or refractory Mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience.' Oncol. Lett. 2013; 5(1): 35-38. [4] Gong, C., et al., 'Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles.' Biomaterials 2013; 34(4): 1413-1432. [5] Haley, B. and E. Frenkel, 'Nanoparticles for drug delivery in cancer treatment.' Urol. Oncol. 2008; 26(1): 57-64. [6] Hanahan, D. and R. A. Weinberg, 'Hallmarks of cancer: the next generation.' Cell 2011; 144(5): 646-674. [7] Lin, Y. G., et al., 'Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.' Clin. Cancer Res. 2007; 13(11): 3423-3430. [8] Milacic, V., et al., 'Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo.' Cancer Res. 2008; 68(18): 7283-7292. [9] Octavia, Y., et al., 'Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.' J. Mol. Cell Cardiol. 2012; 52(6): 1213-1225. [10] Prasad, S., et al., 'Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin: the Golden Pigment from Golden Spice.' Cancer Res. Treat. 2014; 46(1): 2-18. [11] Shakibaei, M., et al. 'Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-kappaB and Src protein kinase signaling pathways.' PLoS One 2013 8(2): e57218. [12] Sharp, F. R. and M. Bernaudin, 'HIF1 and oxygen sensing in the brain.' Nat. Rev. Neurosci. 2014; 5(6): 437-448. [13] Shehzad, A., et al., 'Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials.' Arch. Pharm. (Weinheim) 2010; 343(9): 489-499. [14] Wang, C.-H. and G.-H. Hsiue ., 'Synthesis and characterization of temperature- and pH-sensitive hydrogels based on poly(2-ethyl-2-oxazoline) and poly(D,L-lactide).' Journal of Polymer Science Part A: Polymer Chemistry 2002; 40(8): 1112-1121. [15] Wang, C. H., et al., 'Polymeric micelles with a pH-responsive structure as intracellular drug carriers.' J. Control Release 2005; 108(1): 140-149. [16] Arbiser L., et al (1998). 'Curcumin Is an In Vivo Inhibitor of angiogenesis'Molecular Med. 4: 376-383. [17] Shishodia S., 'Molecular Mechanisms of Curcumin Action: Gene Expression' Biofactors. 2013; 39(1): 37-55. [18] G.S. Kwon and T. Okano, 'Polymeric micelles as new drug carriers' Adv. Drug Deliv. Rev. 1996; 21: 107– 116. [19] Anand P. et al., 'Bioavailability of Curcumin: Problems and Promises' Molecular Pharm. Rev. 2007; [20] Ravindranath V. et al., 'Chandrasekhara, N. Metabolism of curcumin– –studies with [3H]curcumin.' Toxicology.1981; 22 (4): 337–44 [21] Pan M. H., Huang T. M., Lin, J. K. et al., 'Biotransformation of curcumin through reduction and glucuronidation in mice. ' Drug Metab. Dispos. 1999; 27 (4), 486–94. [22] Murray J.C. et al. “Long-Circulating and Target-Specific Nanoparticles:Theory to Practice” Pharmacol Rev. 2001; 53(2):283-318. [23] Muhamad F., “The Role of Curcuma longa Against Doxorubicin (Adriamycin)-Induced Toxicity in Rats” J. Med. Food. 2009; 12(2):394-402. [24] Ajaikumar B., Sushovan G., Sunil Kr. Et al.,” Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappa B-regulated gene products.” Cancer Res. 2007; 67:3853-3861. [25] Gururaj A., Belakavadi M., Deepak A., Venkatesh, Dieter M., Bharathi P and Salimatha,” Molecular mechanisms of anti-angiogenic effect of curcumin” Biochemical and Biophysical Research Communications 2002; 297 934–942. [26] Matsumura Y. and Maeda H. ” A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.” Cancer Res. 1986 Dec; 46(12 Pt 1):6387-92. [27] Hsiue G.H., Wang C.H., Lo C.,Wang C.H., Li J.P,Yang J.L., ” Environmental-sensitive micelles based on poly(2-ethyl-2-oxazoline)-b-poly(l-lactide) diblock copolymer for application in drug delivery” International Journal of Pharmaceutics 2006; 317 9–75 [28] Chen Y.C., Lee W.F., Tsai H.H., Hsieh W.Y, ” Paclitaxel and iron oxide loaded multifunctional nanoparticles for chemotherapy, fluorescence properties, and magnetic resonance imaging.” J. Biomed. Mater. Res. A. 2012; 100(5):1279-92. [29] Satomi O., Haruki T., Yohei K., Yoshiki S., Junya H., Barbara T. and Shizuo Y.,” Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability” Journal of Pharmaceutical Sciences, 2010; Vol. 99, 1871–1881 [30] 蔡吟孟(2011)。薑黃素與其奈米微粒於大鼠體內之藥物動力學研究。博士 論文,國立陽明大學傳統醫藥研究所。 [31] 吳嘉慶(2010)。四氫薑黃素與薑黃素作為癌症化學預防試劑之分子機制。碩士論文,國立海洋科技大學,水產食品科學研究所。 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55054 | - |
dc.description.abstract | 摘要
研究目的: 探討能否藉由Liposomal Doxorubicin搭配奈米薑黃素微胞來增加對腫瘤治療之療效並降低化療對小鼠之副作用。 材料與方法: 本實驗使用之實驗小鼠為周齡4~5周,體重20~22公克Balb/c雄鼠,將小鼠結腸直腸癌細胞(Murine Colorectal Adenocarcinoma) CT-26植入小鼠兩側耳朵皮下。利用電子式游標尺測量腫瘤體積,拍照紀錄並利用電子天平測量小鼠體重。在植入腫瘤後第10天開始治療,腫瘤治療之起始體積為50mm3。 實驗設計組包括: Control組、Free Curcumin(20mg/kg)組、Curcumin Micelles Low Dose(20mg/kg)(CUM20)組、Curcumin Micelles High Dose(40mg/kg)(CUM40)組、PLD Low Dose(4mg/kg)(PLD4)組、PLD High Dose(6mg/kg)(PLD6)組、CUM20+ PLD 6組以及CUM40 + PLD4組。 實驗結果: 單以Curcumin治療不論高劑量(40mg/kg)、低劑量(20mg/kg)以及Free Cucumin(20mg/kg)治療在療程結束後腫瘤體積皆較Control組小並有顯著差異。而高劑量PLD(6mg/kg)搭配Curcumin治療與單用高劑量PLD(6mg/kg)之間在第22天之後開始出現統計上的顯著差異。低劑量PLD(4mg/kg) 搭配Curcumin(40mg/kg)治療與單用高劑量PLD(6mg/kg)其療程結束後抑制腫瘤生長的情況相仿,並且降低對體重下降的副作用。此外,薑黃素在腫瘤組織內的定量包覆成微胞的形式的薑黃素能夠增加其在腫瘤組織內的累積量。 關鍵字: 薑黃素、奈米藥物、癌症治療 | zh_TW |
dc.description.abstract | ABSTRACT
In this study, we investigated whether liposomal doxorubicin combined with curcumin micelles would have synergistic antitumor effect and decrease the chemotherapy side effect on mice. Male Balb/c mice weighing from 19~22g were used in this study, each mouse received subcutaneous implantation of murine colorectal adenocarcinoma CT-26 cells in both ears. The treatments were initialed on Day 10 when the tumor volumes were about 50mm3. Tumor volumes were measured every three days through Day 28 using digital calipers and the body weights were monitored. Experiments comprised eight groups: Control, Free curcumin(20mg/kg), curcumin micelles low dose(20mg/kg)(CUM20), curcumin micelles high dose(40mg/kg)(CUM40), PLD low dose(4mg/kg)(PLD4), PLD high dose(6mg/kg)(PLD6), PLD6 with CUM20 and PLD4 with CUM40. The results showed that curcumin micelles increased more curcumin accumulation in tumor tissue than free curcumin. Tumor volumes treated with free curcumin, CUM20, and CUM40 were significantly smaller than control after 22 day. The present study showed that PLD6 combined with curcumin micelles was more effective than PLD6 alone. Furthermore, tumor growth in group treated with PLD4 combined with CUM40 was similar to that in group treated with PLD6 alone, but it eased the adverse effect caused by PLD chemotherapy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T03:45:38Z (GMT). No. of bitstreams: 1 ntu-103-R01548011-1.pdf: 2967195 bytes, checksum: c08e196bf46b6487732044cf181ea486 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 目錄
誌謝……………………………………………………………………………………I Abstract………………………………………………………………………………..II 摘要………………………………………………………………………………......IV 目錄……………………………………………………………………………….......V 圖目錄………………………………………………………………………………VII 第一章 緒論………………………………………………………………………...1 1.1 腫瘤………………………………………………………………………....1 1.2 血管新生…………………………………………………………………....1 1.3 薑黃素………………………………………………………………………3 1.4 Pegylated Liposomal Doxorubicin(PLD) …………………………………..5 1.5 藥物傳輸……………………………………………………………………6 1.6 奈米藥物……………………………………………………………………6 1.7 PEOz-b-PLAB………………………………………………………………7 1.8 薑黃素奈米粒子……………………………………………………………8 1.9 研究目的…………………………………………………………………...11 第二章 材料與方法………………………………………………………………..13 2.1 腫瘤細胞株………………………………………………………………….13 2.2 動物實驗…………………………………………………………………….13 2.3 小鼠耳朵模型……………………………………………………………….13 2.4實驗設計及流程.............................................................................................14 2.5 Free curcumin 製備........................................................................................16 2.6 薑黃素之吸光光譜.........................................................................................17 2.7 薑黃素血漿中濃度定量……………………………………………….....…17 2.8 薑黃素組織中濃度定量……………………………………………….....…17 2.9數據統計及分析…………………………………………………………….18 第三章 結果..............................................................................................................19 3.1 Control組...........................................................................................................19 3.2 Curcumin micelles low dose組.........................................................................19 3.3 Curcumin micelles high dose組........................................................................19 3.4 Free curcumin組………………………………………………………………20 3.5 PLD high dose組...............................................................................................20 3.6 PLD low dose組................................................................................................20 3.7低劑量薑黃素搭配高劑量PLD(Curcumin20+PLD6組)..................................21 3.8高劑量薑黃素搭配低劑量PLD(Curcumin40+PLD4組) ..................................22 3.9 薑黃素之吸光光譜…………………………………………………………...26 3.10薑黃素之標準曲線…………………………………………………………..27 3.11薑黃素在血漿中之濃度……………………………………………………..28 3.12薑黃素在各組織中之累積濃度……………………………………………..29 3.13 療程結束後腫瘤組織之H&E染色………………………………….……..38 3.14各組治療對小鼠體重的變化情形…………………………………………..43 第四章 討論……………..........................................................................................44 4.1高劑量PLD搭配低劑量curcumin micelles…………………………………44 4.2低劑量PLD搭配高劑量curcumin micelles…………………………………44 4.3 Curcumin micelles與Free curcumin的比較………………………...………45 第五章 結論與未來工作…………………………………………………………..46 第六章 參考文獻......................................................................................................47 | |
dc.language.iso | zh-TW | |
dc.title | 以薑黃素微胞搭配奈米抗癌藥物對腫瘤療效之探討 | zh_TW |
dc.title | Investigation of the Therapeutic Efficacy of Antitumor Nanodrug Combined with Curcumin Micelles | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 謝銘鈞,張富雄 | |
dc.subject.keyword | 薑黃素,奈米藥物,癌症治療, | zh_TW |
dc.subject.keyword | curcumin,nanodrug,cancer treatment, | en |
dc.relation.page | 49 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-02-04 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 2.9 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。